Scisparc: mitocarex bio expands research to pancreatic cancer following initial in-vitro positive results

Tel aviv, israel, jan. 07, 2025 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that mitocarex bio ltd. (“mitocarex”), its joint venture with dr. alon silberman, is expanding its research and development efforts into pancreatic cancer following encouraging initial in-vitro results.
SPRC Ratings Summary
SPRC Quant Ranking